Search research articles
Contact Us
Filters
Showing results (111-120 of 231) with videos related to
Page
of 24
Sort By:
Breast (Edinburgh, Scotland)
|
July 23, 2014
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial
Antonio Llombart-Cussac, Xavier Pivot, Laura Biganzoli, et al.
BMC Cancer
|
June 5, 2016
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
Kathy Miller, Javier Cortes, Sara A Hurvitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
José Baselga, Karen A Gelmon, Shailendra Verma, et al.
Future Oncology (London, England)
|
April 1, 2020
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
Hope S Rugo, Aditya Bardia, Sara M Tolaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2025
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence
Fabio Conforti, Federico Merlo, Laura Pala, et al.
Therapeutic Advances in Medical Oncology
|
March 21, 2022
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer
Aditya Bardia, Javier Cortes, Sara A Hurvitz, et al.
Frontiers in Immunology
|
February 13, 2024
Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis
Isabella Sala, Eleonora Pagan, Laura Pala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 9, 2024
Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis
Michael Untch, David Pérol, Erica L Mayer, et al.
Current Drug Metabolism
|
April 6, 2012
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer
Dan Lu, Howard A Burris, Bei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
Luca Gianni, Anna Lladó, Giulia Bianchi, et al.
Page
of 24
Search research articles
Search
Showing results (111-120 of 231) with videos related to
Sort By:
Page
of 24
Breast (Edinburgh, Scotland)
|
July 23, 2014
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial
Antonio Llombart-Cussac, Xavier Pivot, Laura Biganzoli, et al.
BMC Cancer
|
June 5, 2016
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
Kathy Miller, Javier Cortes, Sara A Hurvitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
José Baselga, Karen A Gelmon, Shailendra Verma, et al.
Future Oncology (London, England)
|
April 1, 2020
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
Hope S Rugo, Aditya Bardia, Sara M Tolaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 17, 2025
Why Adjuvant Treatment With a CDK4/6 Inhibitor Should Be Recommended for Women With High-Risk Breast Cancer: Methodologic Considerations on Available Evidence
Fabio Conforti, Federico Merlo, Laura Pala, et al.
Therapeutic Advances in Medical Oncology
|
March 21, 2022
AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib <i>versus</i> letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer
Aditya Bardia, Javier Cortes, Sara A Hurvitz, et al.
Frontiers in Immunology
|
February 13, 2024
Surrogate endpoints for overall survival in randomized clinical trials testing immune checkpoint inhibitors: a systematic review and meta-analysis
Isabella Sala, Eleonora Pagan, Laura Pala, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 9, 2024
Disease-free survival as a surrogate for overall survival in HR+/HER2- early breast cancer: A correlation analysis
Michael Untch, David Pérol, Erica L Mayer, et al.
Current Drug Metabolism
|
April 6, 2012
Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer
Dan Lu, Howard A Burris, Bei Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
Luca Gianni, Anna Lladó, Giulia Bianchi, et al.
Page
of 24